The ZYCOV-D vaccine candidate was developed by Cadila Healthcare Ltd. based in IndiaA219758. The vaccine was developed using a DNA vaccine platform with a non-replicating and non-integrating plasmid carrying the gene of interestL16503. Once the plasmid DNA is introduced into host cells and the viral protein is translated, it elicits a strong immune response, stimulating the humoral and cellular components of the immune systemL16503. The DNA vaccine platform offers minimal biosafety requirements, more improved vaccine stability, and lower cold chain requirementsL16503. Phase I clinical trials of this vaccine candidate were completed in July 2020, with the company reporting successful dosing and toleranceA219758,L16493. As of August, 2020 the candidate is in Phase II clinical trialsA219758.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.